Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide for Rare Genetic Disorders of Obesity
New designation for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway
Expands upon previous designation for POMC deficiency obesity
BOSTON, May 11, 2017 -- (Healthcare Sales & Mar... Biopharmaceuticals, FDA Rhythm Pharmaceuticals, setmelanotide, obesity
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news